Results for omalizumab translation from English to Latvian

omalizumab
omalizumabs

omalizumab 300 mg
omalizumabs pa 300 mg

endpoint omalizumab 300 mg
12. nedēļa primārais mērķa kritērijs

week omalizumab or placebo administered
nedēļa lietojot omalizumabu vai placebo

one vial contains 150 mg omalizumab.
viens flakons satur 150 mg omalizumaba.

omalizumab studies 1 and 3 pooled
omalizumaba 1. un 3 pētījuma apvienotie rezultāti

one vial contains 150 mg of omalizumab.
viens flakons satur 150 mg omalizumaba (omalizumab).

one vial contains 150 mg of omalizumab*.
viens flakons satur 150 mg omalizumaba (omalizumabum)*.

xolair 150 mg solution for injection omalizumab
xolair 150 mg šķīdums injekcijām omalizumab

the active substance of xolair is omalizumab.
xolair aktīvā viela ir omalizumabs.

there are no human fertility data for omalizumab.
nav datu par omalizumaba ietekmi uz fertilitāti cilvēkiem.

xolair 150 mg solution for injection omalizumab sc use
xolair 150 mg šķīdums injekcijām omalizumab s. c. lietošanai

1 ml solution for injection contains 150 mg omalizumab.
1 ml šķīduma injekcijām satur 150 mg omalizumaba.

xolair 150 mg powder for solution for injection omalizumab
xolair 150 mg pulveris injekciju šķīduma pagatavošanai omalizumabum

xolair is also available in vials with 150 mg omalizumab.
xolair ir pieejams arī flakonos pa 150 mg omalizumaba.

it is unknown whether omalizumab is excreted in human milk.
nav zināms, vai omalizumabs izdalās cilvēka pienā.

in vitro, omalizumab forms complexes of limited size with ige.
in vitro omalizumabs veido ierobežota lieluma kompleksus ar ige.

the maximum recommended dose is 600 mg omalizumab every two weeks.
maksimālā ieteicamā deva ir 600 mg omalizumaba reizi divās nedēļās.

the active substance in xolair, omalizumab, is a monoclonal antibody.
xolair aktīvā viela omalizumabs ir monoklonāla antiviela.

milk levels of omalizumab were 0.15% of the maternal serum concentration.
omalizumaba līmenis pienā bija 0,15% no koncentrācijas mātītes serumā.